<DOC>
	<DOCNO>NCT01513941</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety telaprevir , give pegylated-interferon-alfa-2a ( Peg-IFN-alfa-2a ) ribavirin ( RBV ) treatment hepatitis C patient infect chronic hepatitis C virus ( HCV-1 ) human immunodeficiency virus ( HIV-1 ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Telaprevir Patients Infected With Both Chronic Hepatitis C Virus ( HCV-1 ) Human Immunodeficiency Virus ( HIV-1 )</brief_title>
	<detailed_description>This open-label ( participant investigator know name medication give certain moment ) , single-arm , multicenter study HCV treatment-naive treatment-experienced patient infect chronic HCV-1 HIV-1 determine efficacy safety telaprevir give Peg-IFN-alfa-2a RBV . The study consist 3 phase : screening phase , open-label treatment phase 48 week , follow-up period 24 week . All patient receive 12 week treatment telaprevir give Peg-IFN-alfa-2a RBV . At week 12 telaprevir dose end patient continue Peg-IFN-alfa-2a RBV . The total treatment duration study 24 48 week depend patient 's prior HCV treatment status , liver disease status , individual on-treatment virologic response study ( equal response guide therapy ) . The maximum total duration participation study individual participant approximately 76 week ( screen include ) . Approximately 150 patient infected chronic HCV-1 HIV-1 plan enrol .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic ( detectable HCV Ribonucleic acid ( RNA ) 6 month prior screen histological diagnosis base liver biopsy fibroscan ) HCV infection genotype 1 HCV RNA level great 1,000 IU/mL Confirmed diagnosis HIV1 infection great 6 month screen visit CD4 count great 300 cells/mm3 screen value le 200 cells/mm3 within 6 month screen visit HIV1 RNA undetectable ultrasensitive assay least within 90 day screen visit No HIV RNA value great 200 copies/mL within 6 month screen visit Currently take one permit antiHIV regimen great equal to12 week Anticipated need switch antiHIV regimen screen Telaprevir treatment period Infection coinfection HCV genotype 1 Contraindication administration PegIFNalfa RBV Hepatitis B virus ( HBV ) coinfection Acute active condition HIVassociated opportunistic infection within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype 1 chronic hepatitis C</keyword>
	<keyword>Treatment experience HCV-1/HIV-1 coinfection</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Pegylated-Interferon-alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>HCV-1/HIV-1 coinfection</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>